Abstract: Disclosed is an antibody and use thereof. The antibody or antigen binding fragment includes CDR sequences selected from at least one of heavy-chain variable region CDR sequences: SEQ ID NOs: 1-3; and light-chain variable region CDR sequences: SEQ ID NOs: 4-6. The antibody prepared by the present disclosure can effectively bind to the ?3 domain of MICA or MICB, and further, promote the binding of NKG2D to MICA and/or MICB, and can effectively treat or prevent related diseases mediated by MICA and/or MICB, such as promoting the killing of tumors by NK cell.

Abstract: The preset disclosure provides methods of culturing cells, e.g., pluripotent cells, multipotent cells, and/or immune cells (e.g., T cells and/or NK cells) in a medium comprising at least about 5 mM potassium ion, wherein the medium is not hypertonic. In some aspects, the medium is hypotonic. In some aspects, the methods disclosed herein increases the number of less-differentiated cells in the population of cells. In some aspects, the cultured cells are engineered, e.g., to comprise a chimeric antigen receptor or an engineered T cell receptor. In some aspects, the cells are administered to a subject in need thereof.

Abstract: The preset disclosure provides chimeric activation receptors comprising (i) a TGF?-binding domain and (ii) a CD2 costimulatory domain. In some aspects, the TGF?-binding domain comprises an extracellular domain of a TGF? receptor. Other aspects of the disclosure are directed to nucleic acid molecules encoding a chimeric activation receptor, cells comprising the chimeric activation receptor and/or a nucleic acid molecule encoding the same, and methods of use thereof in the treatment of a disease or condition (e.g., a tumor) in a subject in need thereof.

Abstract: Disclosed herein are methods of culturing immune cells in a medium comprising at least about 5 mM potassium ion, wherein the medium is capable of increasing the stemness of the immune cells. In some aspects, the immune cells which are cultured using the methods provided herein are modified to overexpress c-Jun and/or comprise one or more exogenous nucleotide sequences encoding a ligand binding protein. In some aspects, the immune cells are administered to a subject in need thereof.

Abstract: Disclosed herein are methods of culturing immune cells in a medium comprising at least about 5 mM potassium ion, wherein the medium is capable of increasing the stemness of the immune cells. In some aspects, the immune cells which are cultured using the methods provided herein are modified to express a ROR1-binding protein and have increased level of c-Jun protein. In some aspects, the immune cells are administered to a subject in need thereof.

Abstract: Provided is an antibody or antibody fragment. The antibody or the antibody fragment includes HCDR1 selected from GYTFSSFS, GYTFSTFA, or GYSFTAYT, HCDR2 selected from ILPGSNST, ILPGINNT, ILPGGNNT, or INPYNGGT, and HCDR3 selected from SSYWFAY, STYWFAY, or AREGNYYGSRGDFDY; and LCDR1 selected from QSLLNSGNQKNY or QTIVTN, LCDR2 selected from GAS or YAS, and LCDR3 selected from QNAHSYPPT, QNAHSYPPA, or QQSHSWPFT. The provided antibody can be used for treating cancer.

Abstract: The present disclosure provides methods of preparing immune cells, e.g., T cells and/or NK cells, comprising contacting the cells with programmable cell-signaling scaffolds in a medium comprising at least about 5 mM potassium ion. In some aspects, the methods disclosed herein increase the number of less-differentiated cells in the population of cells. In some aspects, the cultured cells are engineered, e.g., to comprise a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR). In some aspects, the cells are administered to a subject in need thereof.

Abstract: The present disclosure provides methods of promoting a persistent effector function of immune cells, comprising modifying the cells to overexpress c-Jun and reduced levels of a NR4A gene and/or protein. Also provided are modified cells, e.g., immune cell, which have been modified to overexpress c-Jun and express reduced levels of NR4A gene and/or protein. Overexpressing c-Jun and simultaneously reducing expression levels of a NR4A gene and/or protein leads to exhaustion/dysfunction resistant cells, which are apoptosis resistant and also immune checkpoint resistant, and also to the maintenance of anti-tumor function in tumor microenvironments.

Abstract: The present disclosure relates to polynucleotides encoding a chimeric polypeptide comprising a c-Jun polypeptide, a ROR1-binding protein, and a truncated EGF receptor. Also provided are cells (e.g., T cells) expressing CARs comprising a ROR1-binding protein and overexpressing a c-Jun polypeptide. Overexpression of c-Jun in CAR T cells confers improved properties, e.g., reducing or preventing exhaustion.

Abstract: Disclosed herein are polynucleotides comprising a nucleotide sequence encoding an AP-1 transcription factor (i.e., c-Jun). In some aspects, the nucleotide sequence is codon-optimized. In some aspects, the polynucleotides comprise one or more additional nucleotide sequences encoding a linker, signal peptide, antigen-binding domain, spacer, transmembrane domain, costimulatory domain, intracellular signaling domain, truncated EGFR, and combinations thereof. Also disclosed herein are cells, vectors, and pharmaceutical compositions comprising such polynucleotides. The use of such polynucleotides, cells, vectors, and pharmaceutical compositions to treat a disease or disorder (e.g., cancer) is also provided.

Abstract: The preset disclosure provides methods of culturing TILs in a medium comprising at least about 30 mM to at least about 100 mM potassium ion. In some aspects, the methods disclosed herein enhance expansion of CD8+ TILs, relative to CD4+ TILs. In some aspects, the methods further increase the number of less-differentiated cells, e.g., less-differentiated TILs, in the population of cells. In some aspects, the methods disclosed herein enrich for tumor-reactive, e.g., tumor specific, TILs such that clonal diversity is preserved. In some aspects, the cells, e.g., the TILs, are administered to a subject in need thereof. 17667030.

Abstract: The present disclosure related to chimeric antigen receptors (CARs) comprising immunoglobulin (Ig) derived spacers, e.g., hinge or loop regions, fragments thereof, or combinations thereof. Ig derived spacer confers improved properties to the CARs, e.g., increased cytokine release with respect the CARs with spacers not derived from hinge regions and fragments thereof, loop regions from constant domains and fragments thereof, and combinations thereof. Also provided are cells expressing CARs comprising Ig derived spacers regions and methods to use the CARs to treat diseases or disorders, e.g., cancer. Some of the disclosed Ig derived spacers are fragments from, e.g., IgA1, IgA2, IgD, IgE, IgG1, IgG2, IgG3, IgG4, or IgM. In some aspects, the disclosed Ig derived spacers are derived from non-human immunoglobulins, e.g., mouse immunoglobulins such IgG2A. Other Ig derived spacer disclosed are modular constructs comprising several concatenated Ig hinges or fragments thereof.

Abstract: The preset disclosure provides methods of culturing cells, e.g., pluripotent cells, multipotent cells, and/or immune cells (e.g., T cells, NK cells, and/or TILs) in a medium comprising at least about 5 mM potassium ion, wherein the medium is not hypertonic. In some aspects, the medium is hypotonic. In some aspects, the methods disclosed herein increases the number of less-differentiated cells in the population of cells. In some aspects, the cultured cells are engineered, e.g., to comprise a chimeric antigen receptor or an engineered T cell receptor. In some aspects, the cells are administered to a subject in need thereof.

Abstract: The present disclosure relates to EGFR-derived polypeptides containing short juxtamembrane sequences, nucleic acids encoding them, and methods of using them to improve cell surface expression of truncated EGFR markers.

Abstract: Extracts of Agaricus blazei Murill have been found to have anti-tumor activity. In particular, a polar, high molecular weight fraction of an Agaricus blazei Murill extract has been found which has an inhibitory effect on legumain activity. Extracts of Agaricus blazei Murill can be used in a pharmaceutical composition to inhibit cysteine protease legumain in a patient suffering from a tumor thereby treating the tumor and preventing new tumors.

Abstract: Extracts of Agaricus blazei Murill have been found to have anti-tumor activity. In particular, a polar, high molecular weight fraction of an Agaricus blazei Murill extract has been found which has an inhibitory effect on legumain activity. Extracts of Agaricus blazei Murill can be used in a pharmaceutical composition to inhibit cysteine protease legumain in a patient suffering from a tumor thereby treating the tumor and preventing new tumors.